CN112274639B - Fe2C@Fe3O4异质纳米颗粒、制备方法及用途 - Google Patents
Fe2C@Fe3O4异质纳米颗粒、制备方法及用途 Download PDFInfo
- Publication number
- CN112274639B CN112274639B CN202011184536.5A CN202011184536A CN112274639B CN 112274639 B CN112274639 B CN 112274639B CN 202011184536 A CN202011184536 A CN 202011184536A CN 112274639 B CN112274639 B CN 112274639B
- Authority
- CN
- China
- Prior art keywords
- nanoparticles
- heterogeneous
- peg
- particles
- heterogeneous nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 168
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 229910017356 Fe2C Inorganic materials 0.000 title 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 title 1
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000002789 catalaselike Effects 0.000 claims abstract description 9
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 3
- 238000010079 rubber tapping Methods 0.000 claims abstract description 3
- 238000003763 carbonization Methods 0.000 claims abstract 2
- 238000011068 loading method Methods 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 26
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadecene Natural products CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 238000012632 fluorescent imaging Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 29
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000001788 irregular Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 143
- 241000699670 Mus sp. Species 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000002086 nanomaterial Substances 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000001239 high-resolution electron microscopy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/90—Carbides
- C01B32/914—Carbides of single elements
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/02—Oxides; Hydroxides
- C01G49/08—Ferroso-ferric oxide [Fe3O4]
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/30—Particle morphology extending in three dimensions
- C01P2004/40—Particle morphology extending in three dimensions prism-like
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/80—Particles consisting of a mixture of two or more inorganic phases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了Fe2C@Fe3O4异质纳米颗粒、制备方法及用途。将结晶Fe碳化为Fe2C后氧化开孔形成Yolk‑Shell结构的Fe2C@Fe3O4异质纳米颗粒,Fe3O4壳布列形状不规则的孔洞。该异质纳米颗粒的光学和磁学性能均高于Fe2C纳米颗粒及空心Fe3O4纳米颗粒,磁光热性能显著提高。Fe2C@Fe3O4异质纳米颗粒还可通过自身所具有的类过氧化氢酶活性催化H2O2分解产生羟基自由基(·OH)发挥抗菌疗效。此外,磁光热性能产生的高热可增强类过氧化氢酶活性,进而增强抗菌性能。将Ce6载入Fe2C@Fe3O4异质纳米颗粒,还可实现诊疗一体化。
Description
技术领域
本发明涉及纳米材料及其制备方法和用途,特别涉及Fe2C@Fe3O4异质纳米颗粒、制备方法及用途。
背景技术
细菌感染是由致病菌或条件致病菌所引起的一类感染性疾病,具有高治病率及高死亡率,已成为一项全球健康问题。针对细菌感染类疾病,抗生素作为首选药物呈现出良好的抗菌疗效,但随着抗生素的滥用,出现了越来越多的耐药菌株,如MRSA、MDRPA,导致疾病不断地恶化。随着纳米技术的不断发展,越来越多的无机纳米材料被应用于抗菌治疗,如氧化铁、石墨烯、多巴胺等。与传统的抗生素相比,纳米材料用于抗菌治疗不易产生耐药性、生物安全性高且具有靶向性。
近几年,研究者发现利用纳米材料的光热性能或磁热性能产生的高热可有效地杀死细菌,其杀菌机制为破坏细菌的细胞膜,导致细菌细胞渗透性增加。利用高热抗菌具有深组织穿透性、不易产生耐药菌、抗菌谱广、可远程操控等优点,是一种非侵入性的治疗手段。然而有研究表明,完全杀死细菌的温度需达到70℃,而正常细胞在短时间内能够承受的温度为50~60℃,这就意味着仅依靠高热并不能到达很好的抗菌疗效。
与单一疗法相比,联合疗法抗菌效果好且生物安全性高,在抗菌领域得到了广泛的应用。具备两种不同的材料成分和表面的两面神结构的异质纳米颗粒可以同时结合两种材料性能,实现联合治疗。据报道,铁基纳米材料具有类酶活性,可催化H2O2分解产生·OH,·OH作活性氧的一种,可通过破坏细菌细胞膜,干扰DNA的复制、转录、翻译过程抑制细菌的生长。其中,Fe2C纳米材料已被证实具有良好的光热性能及磁热性能,Fe3O4纳米材料具有良好的磁热性能。此外,多孔纳米材料具有能携带荧光染料的孔隙,可用于指示感染部位或者反映感染部位细菌浓度,有助于细菌感染类疾病的诊断。因此,如何利用制备出结合Fe2C和Fe3O4的多孔异质纳米颗粒,通过一定修饰手段制成诊疗一体化的材料成为有待解决的问题。
发明内容
发明目的:本发明目的是提供具有光热效果、磁热效果、磁光热效果、抗菌效果、类过氧化氢酶活性等性能的Fe2C@Fe3O4异质纳米颗粒。
本发明另一目的是提供所述Fe2C@Fe3O4异质纳米颗粒的制备方法。
本发明最后一目的是提供所述Fe2C@Fe3O4异质纳米颗粒的用途。
技术方案:本发明提供一种Fe2C@Fe3O4异质纳米颗粒,将结晶Fe碳化为Fe2C后氧化开孔形成Yolk-Shell结构的Fe2C@Fe3O4异质纳米颗粒,Fe3O4壳布列形状不规则的孔洞。
所述的Fe2C@Fe3O4异质纳米颗粒的制备方法,包括如下步骤:
(1)Fe纳米颗粒的合成:
将NH4Br、十八烯(ODE)、油胺(OAm)混合后密封,持续通入Ar/H2,升温后注入Fe(CO)5反应,降温、离心,得Fe纳米粒子,分散于有机溶剂中保存;
(2)Fe2C纳米颗粒的合成:
将十八烯(ODE),油胺(OAm)和(1)合成的Fe纳米粒子混合后密封,通入Ar/H2、升温,反应完成后降温、离心,将分离出来的Fe2C纳米粒子分散于有机溶剂中保存;
(3)Fe2C@Fe3O4异质纳米颗粒的合成:
将C3H9NO、十八烯(ODE)、Fe2C纳米粒子混合,通入Ar/H2、升温,反应完成后降温、离心,将分离出来的Fe2C@Fe3O4纳米粒子分散于有机溶剂中保存。
一种Fe2C@Fe3O4-PEG异质纳米颗粒,由Fe2C@Fe3O4异质纳米颗粒经DIB-PEG-NH2修饰获得。
所述的Fe2C@Fe3O4-PEG异质纳米颗粒的制备方法,将DIB-PEG-NH2溶解,加入含有Fe2C@Fe3O4异质纳米颗粒的氯仿溶液,超声破碎,即得。
一种Fe2C@Fe3O4-Ce6异质纳米颗粒,为装载Ce6的Fe2C@Fe3O4异质纳米颗粒。
所述的Fe2C@Fe3O4-Ce6异质纳米颗粒的制备方法,将Fe2C@Fe3O4-PEG、Ce6混合,真空、避光条件下搅拌,即得。
进一步地,所述的Fe2C@Fe3O4异质纳米颗粒,具有光热效果、磁热效果、磁光热效果、抗菌效果、类过氧化氢酶活性。
进一步地,所述的Fe2C@Fe3O4-Ce6异质纳米颗粒,Ce6进入Fe3O4壳的孔洞中,进而能够指示细菌感染部位,作为荧光成像探针。
上述技术方案中:
本发明的Fe2C@Fe3O4异质纳米颗粒具有优良的光热效果。在808nm近红外光(NIR)照射下,Fe2C@Fe3O4异质纳米颗粒产生的温度变化明显高于Fe2C纳米颗粒及Fe3O4纳米颗粒。
本发明的Fe2C@Fe3O4异质纳米颗粒具有优良的磁热效果。在交变磁场(AMF)作用下,Fe2C@Fe3O4异质纳米颗粒产生的温度变化明显高于Fe2C纳米颗粒及Fe3O4纳米颗粒。
本发明的Fe2C@Fe3O4异质纳米颗粒具有优良的磁光热效果。在808nm近红外光及交变磁场共同作用下,Fe2C@Fe3O4异质纳米颗粒产生的温度变化近乎达到该异质纳米颗粒光热性能和磁热性能产生温度变化的总和,出现“1+1>2”现象。
本发明的Fe2C@Fe3O4异质纳米颗粒具有热增强的类过氧化氢酶活性。在808nm近红外光及交变磁场共同作用下,Fe2C@Fe3O4异质纳米颗粒产生的高热进一步增强本身所具有的类过氧化氢酶活性,产生更多的羟基自由基(·OH)。
本发明还提供了一种荧光成像探针,通过该探针能实现对细菌感染部位的荧光成像。Fe2C@Fe3O4异质纳米颗粒与Ce6混合后,Ce6进入Fe3O4壳的孔洞中,进而能够指示细菌感染部位。
本发明的Fe2C@Fe3O4异质纳米颗粒具有在抗菌方面的应用,磁光热性能产生的高热协同酶催化产生的·OH对细菌造成了不可逆的杀伤。
本发明的Fe2C@Fe3O4异质纳米颗粒呈现Yolk-shell结构且Fe3O4壳布列形状不规则的孔洞。
本发明的Fe2C@Fe3O4异质纳米颗粒具有优良的光热性能、磁热性能、磁光热性能及类过氧化氢酶活性,可通过本领域技术人员已知的各种化学修饰使之具有亲水性和生物相容性,从而进入生物体进行抗菌治疗。
Fe2C@Fe3O4-PEG异质纳米颗粒经DIB-PEG-NH2修饰获得。经DIB-PEG-NH2修饰后,亲水性和生物相容性增强,有利于进入生物体进行抗菌治疗。
将经DIB-PEG-NH2修饰的Fe2C@Fe3O4异质纳米颗粒简称为Fe2C@Fe3O4-PEG异质纳米颗粒。装载Ce6的Fe2C@Fe3O4异质纳米颗粒简称为Fe2C@Fe3O4-Ce6异质纳米颗粒。
本发明提供的异质纳米颗粒可以分散在任何适于临床应用的生理盐水或缓冲盐溶液中,以注射剂或点滴法施用至机体。
本发明的Fe2C@Fe3O4异质纳米颗粒经DIB-PEG-NH2修饰程度的只要能满足使Fe2C@Fe3O4-PEG稳定的在机体中循环即可。
所述Fe2C@Fe3O4-PEG异质纳米颗粒中,Fe2C@Fe3O4-PEG与DIB-PEG-NH2的摩尔比优选为1∶1~5,进一步优选的可以为1∶4。
在本发明的方案中,施用Fe2C@Fe3O4-PEG异质纳米颗粒的量可根据杀菌温度决定,相应Fe2C@Fe3O4-PEG异质纳米颗粒的施用量以分散在生理盐水或缓冲盐中的Fe浓度量计。
在本发明的实施方式中,对小鼠施用Fe2C@Fe3O4-PEG异质纳米颗粒的量可以是10~25mg/kg小鼠体重,优选的为18~20mg/kg小鼠体重。在上述范围施用该异质纳米颗粒可获得良好的抗菌效果,并基本无明显副作用。
本发明的Fe2C@Fe3O4-PEG异质纳米颗粒可以通过静脉、皮下注射或点滴法对机体进行施用,以通过磁光热治疗及·OH的产生抑制和杀伤细菌。
在本发明的一个具体实施方式中,Fe2C@Fe3O4-PEG异质纳米颗粒制备方法包括将100mg DIB-PEG-NH2溶解到20mL的氯仿中,加入到含有25mg Fe2C@Fe3O4-PEG的5mL氯仿溶液中。该混合溶液超声破碎30min后,旋转蒸发除去氯仿,透析24h除去未反应的DIB-PEG-NH2及氯仿。
有益效果:本发明具有如下优势:
1、本发明的Fe2C@Fe3O4-PEG异质纳米颗粒,同时具备Fe2C和Fe3O4材料的特性。
2、本发明的Fe2C@Fe3O4-PEG异质纳米颗粒与传统单指异质纳米颗粒相比,由于具备不同材料造成的协同作用,因而具有更好光热效果及磁热效果。
3、本发明使用的Fe2C@Fe3O4-PEG异质纳米颗粒所具有的磁热性能和光热性能具有加和性,表现出良好的磁光热效果。
4、本发明使用的Fe2C@Fe3O4-PEG异质纳米颗粒因磁光热性能产生的高热会进一步增强本身类过氧化氢酶活性,表现出更强的酶活性。
5、本发明的Fe2C@Fe3O4-PEG异质纳米颗粒装载Ce6后,可对感染部位做荧光成像。
6、本发明的Fe2C@Fe3O4-PEG异质纳米颗粒通过简单方法即可获得并具有稳定的性能。利用Fe2C@Fe3O4-PEG异质纳米颗粒进行抗菌治疗,能获得显著的杀菌效果,同时生物体没有出现体重降低、以及心、肝、脾、肺、肾功能损伤等副作用。
附图说明
图1为Fe2C@Fe3O4异质纳米颗粒的制备路径图,Fe2C纳米颗粒的电镜图(a),Fe2C@Fe3O4异质纳米颗粒的电镜图(b)和高分辨电镜图(c);
图2为Fe2C@Fe3O4异质纳米颗粒、Fe2C纳米颗粒、Fe3O4纳米颗粒的XRD图;
图3为Fe2C@Fe3O4-PEG异质纳米颗粒在不同溶液中的水和动力学尺寸结果图;
图4为Fe2C@Fe3O4-PEG异质纳米颗粒的光热性能(a),磁热性能(b),磁光热性能(c)
图5为Fe2C@Fe3O4-PEG异质纳米颗粒的类过氧化氢酶活性,室温组(a),AMF及NIR处理组(b);
图6为经不同处理方法处理后,S.aureus(25923)和E.coli(25922)平板涂布照片;
图7为经不同处理方法处理后,S.aureus(25923)和E.coli(25922)扫描电镜结果;
图8经不同处理方法处理后小鼠创口愈合情况;
图9经不同处理方法处理后小鼠荧光成像结果,生理盐水组(左),Fe2C@Fe3O4-Ce6组(右);
图10经不同处理方法处理后小鼠体重的变化,误差线是3只小鼠的体重标准差;
图11经不同处理方法处理后,各组小鼠主要脏器的H&E染色结果。标尺长度为100μm。
具体实施方式
以下实验中涉及的原材料来源:
人宫颈癌细胞-Hela细胞购自协和医院细胞库。
BALB/c小鼠购自南京青龙山动物繁殖场,雌性,体重18~20g。
十八烯,油胺,NH4Br,2’,7’-二氯荧光黄双乙酸盐(DCFH-DA),新吲哚菁绿(Ce6),2-硝基苯基-β-D-吡喃半乳糖苷(ONPG)购自Aladdin公司;无水三甲基胺N-氧化物(C3H9NO)购自东京化成工业株式会社;醋酸钠购自西陇科技股份有限公司;过氧化氢,丙酮购自南京化学试剂股份有限公司;正己烷购自上海泰坦科技股份有限公司;对苯二甲酸(TA),3,3’,5,5’-四甲基联苯胺(TMB)购自科技有限公司;钙黄绿素(Calcein-AM),碘化丙啶(PI),购自Sigma-Aldrich公司。
胰酶,细胞培养基购自江苏凯基生物技术股份有限公司,胎牛血清购自兰州荣晔生物科技有限责任公司。
本实施例的多模态成像的探针制备过程如下:
1、Fe2C@Fe3O4-PEG异质纳米颗粒的制备过程:
1)Fe纳米颗粒的合成:
在250mL四口瓶中加入1-10mg NH4Br,20-50mL十八烯(ODE),1-3mL油胺(OAm),混合均匀后将四口瓶密封,置于加热套中,持续通入Ar/H2。在磁力搅拌下升温至120℃后,抽真空30min并再次通入标准气。继续升温至180℃后用注射器注入0.1ml Fe(CO)5,保持该温度恒定反应30min。待溶液降至室温后,8000rpm离心5min,将离心出来的Fe纳米粒子重新分散于正己烷中保存。
2)Fe2C纳米颗粒的合成:
将5-15mL十八烯(ODE),5-10mL油胺(OAm)和第一步合成的Fe纳米粒子加入250mL四口瓶,磁力搅拌混合均匀。将四口瓶密封,并在Ar/H2保护下升温至120℃,保持温度恒定反应40min。抽真空30min除去溶液中的杂质及正己烷后,再次通入标准气,40min内升温至300℃,反应1h。冷却至室温后,8000rpm离心5min,将分离出来的Fe2C纳米粒子重新分散于正己烷中保存。图1a显示了Fe2C纳米颗粒的形貌。
3)Fe2C@Fe3O4异质纳米颗粒的合成:
在250mL四口瓶中加入5-30mg C3H9NO、10mL十八烯(ODE),新鲜合成的Fe2C纳米粒子。将四口瓶置于加热套中,并保持Ar/H2流通和磁力搅拌。将温度升至120℃后持续通入惰性气体保持温度恒定1h。120℃条件下真空泵抽气40min,并再次通入标准气,保证反应在还原性气氛下进行,随后以2℃/min的速率升温至220℃反应10min。待溶液冷却至室温后,8000rpm离心5min收集Fe2C@Fe3O4异质纳米颗粒,将其置于正己烷中保存。图1b,1c显示了Fe2C@Fe3O4异质纳米颗粒的形貌
4)Fe2C@Fe3O4-PEG异质纳米颗粒的制备:将100mg DIB-PEG-NH2溶解到20mL的超纯水中,加入含有25mg Fe2C@Fe3O4的5mL氯仿溶液。该混合溶液超声破碎30min,旋转蒸发除去氯仿。将产物分散在超纯水中,透析24h除去未反应的DIB-PEG-NH2,即可获得Fe2C@Fe3O4-PEG异质纳米颗粒水溶液。
2、Fe2C@Fe3O4-Ce6异质纳米颗粒的制备过程:
取500μl Fe2C@Fe3O4-PEG(58μg/m1)、10μl Ce6(2mg/ml)放入单口瓶中,用真空泵抽去瓶内空气,在避光条件下磁力搅拌24h。
3、Fe2C@Fe3O4-PEG异质纳米颗粒的相关性能
1)Fe2C@Fe3O4-PEG异质纳米颗粒的表征图。
图2显示了Fe2C@Fe3O4异质纳米颗粒的XRD图,证明材料由Fe2C及Fe3O4两种成分组成。图3显示了Fe2C@Fe3O4-PEG异质纳米颗粒在不同溶液中的水和动力学尺寸,证明了材料的稳定性。
2)Fe2C@Fe3O4-PEG异质纳米颗粒的光热性能。
Fe2C@Fe3O4-PEG在近红外光(808nm)的照射下将光能转化为热能,进而产生高热。图4a显示了Fe2C@Fe3O4-PEG异质纳米颗粒、Fe2C纳米颗粒、Fe3O4纳米颗粒的光热性能。取100μl浓度为200μg/ml的Fe2C@Fe3O4-PEG异质纳米颗粒、Fe2C-PEG纳米颗粒、Fe3O4-PEG纳米颗粒于96孔板中,用波长808nm的近红外光照射5min,记录温度变化。从图4a可以看出,Fe2C@Fe3O4-PEG异质纳米颗粒产生的温度变化高于Fe2C-PEG纳米颗粒、Fe3O4-PEG纳米颗粒,说明Fe2C@Fe3O4-PEG异质纳米颗粒的光热性能强于Fe2C纳米颗粒、Fe3O4纳米颗粒。
3)Fe2C@Fe3O4-PEG异质纳米颗粒的磁热性能。
图4b显示了Fe2C@Fe3O4-PEG异质纳米颗粒、Fe2C纳米颗粒、Fe3O4纳米颗粒的磁热性能:将100μl相同浓度的Fe2C@Fe3O4-PEG异质纳米颗粒、Fe2C纳米颗粒、Fe3O4纳米颗粒装在0.2mL Ependoff管中,随后将Ependoff管放入线圈中,参数为:H=25kA/m,t=5min。用近红外成像仪记录温度变化,进而评价磁热性能强弱。图4b显示由Fe2C@Fe3O4-PEG异质纳米颗粒产生的温度变化明显高于Fe2C纳米颗粒、Fe3O4纳米颗粒,说明Fe2C@Fe3O4-PEG异质纳米颗粒的磁热性能强于Fe2C纳米颗粒、Fe3O4纳米颗粒。
4)Fe2C@Fe3O4-PEG异质纳米颗粒的磁光热性能。
图4c显示了单独或同时用交变磁场(25kA/m)及808nm近红外光(0.5W/cm2)处理Fe2C@Fe3O4-PEG异质纳米颗粒引起的温度变化。图4b显示同时用交变磁场及近红外光处理Fe2C@Fe3O4-PEG异质纳米颗粒所产生的温度变化高于单独用交变磁场及近红外光处理引起的温度变化,且出现“1+1>2”的现象,说明Fe2C@Fe3O4-PEG异质纳米颗粒具有优良的磁光热性能。
5)Fe2C@Fe3O4-PEG异质纳米颗粒的类过氧化氢酶活性。
3,3’,5,5’-四甲基联苯胺(TMB)可被高活性的·OH氧化,产生无色至蓝色的显色反应,在652nm处检测蓝色的吸光度,根据吸光值的强弱评价酶活性的高低。图5显示了TMB与不同物质孵育后的紫外吸收曲线变化图。该结果显示:Fe2C@Fe3O4-PEG异质纳米颗粒与H2O2共孵育后,652nm处有明显紫外吸收,说明Fe2C@Fe3O4-PEG异质纳米颗粒能够催化H2O2分解产生·OH,具有类过氧化氢酶活性。AMF及NIR处理后,652nm处紫外吸收值明显升高,说明磁场及激光处理后产生的高热能进一步增强其类过氧化氢酶活性。
6)体外细菌实验结果
用新鲜的LB液体培养基稀释处于对数生长期的S.aureus(25923)和E.coli(25922)悬液,菌液浓度为4×109CFU/ml。将其分为7组:1、对照组;2、NIR+MHT;3、H2O2;4、Fe2C@Fe3O4-PEG;5、Fe2C@Fe3O4-PEG+NIR+MHT;6、Fe2C@Fe3O4-PEG+H2O2;7、Fe2C@Fe3O4-PEG+H2O2+NIR+MHT,Fe2C@Fe3O4-PEG、H2O2的最终浓度分别为100μg/ml和100μM。37℃下共孵育2h后,2、4、7三组用AMF(25kA/m)及808nm近红外光(0.75W/cm2)处理10min。再孵育2h后,用无菌生理盐水稀释菌液(菌液:生理盐水=1∶108),取100μl涂平板,37℃培养12h,记录平板上菌落数目。
如图6所示,5组产生的高热及6组产生的·OH均能在一定程度上杀死细菌。但相比之下,7组的杀菌效果更加显著。说明Fe2C@Fe3O4-PEG异质纳米颗粒能协同自身的磁光热性能及酶活性对细菌造成严重的损伤,是一种优良的抗菌材料。
进一步使用扫描电镜观察单个细菌细胞形态。将浓度为4×109CFU/ml的S.aureus(25923)和E.coli(25922)悬液分为5组:(1)对照组;(2)Fe2C@Fe3O4-PEG;(3)Fe2C@Fe3O4-PEG+NIR+MHT;(4)Fe2C@Fe3O4-PEG+H2O2;(5)Fe2C@Fe3O4-PEG+H2O2+NIR+MHT,37℃下孵育2h后,(3)、(4)组用AMF(25kA/m)及808nm近红外光(0.75W/cm2)处理10min。离心获得细菌细胞后,用PBS洗涤三次,2.5%的戊二醛固定8h。50%、70%、80%、90%、95%、100%的乙醇进行梯度脱水,每次30min,最后经干燥、喷金后在电镜下观察。如图7所示,对照组细菌细胞饱满,表面光滑无褶皱,用Fe2C@Fe3O4-PEG、Fe2C@Fe3O4-PEG+NIR+MHT、Fe2C@Fe3O4-PEG+H2O2处理后细菌细胞表面出现不同程度的褶皱,Fe2C@Fe3O4-PEG+H2O2+NIR+MHT处理后细菌细胞表面皱缩程度最严重,且部分细胞发生破碎,证明纳米材料具有协同杀菌性能。此结果与平板计数法所得结果一致。
7)小鼠体内实验结果
7.1小鼠体内抗菌结果:
小鼠模型:用外科剪在BALB/c(18~20g)小鼠背部剪出一个直径为8mm的类圆形伤口,接种20μl E.coli(25922)悬液,浓度为1.0×1010CFU/mL。24h后,取伤口处的渗出液进行平板计数,判断模型是否构建成功。
将小鼠分为7组,每组3只:(1)对照组;(2)NIR+MHT;(3)H2O2;(4)Fe2C@Fe3O4-PEG;(5)Fe2C@Fe3O4-PEG+NIR+MHT;(6)Fe2C@Fe3O4-PEG+H2O2;(7)Fe2C@Fe3O4-PEG+H2O2+NIR+MHT。Fe2C@Fe3O4-PEG浓度为100μg/ml,H2O2浓度为100μM,近红外光强度为(0.75W/cm2),交变磁场强度为(25kA/m),时间为5min。利用近红外成像仪记录温度变化。如图8所示,处理7天后,1、2、3、4组小鼠伤口无明显变化;5组和6组小鼠伤口明显减小,说明Fe2C@Fe3O4-PEG纳米材料在体内同样可发挥磁光热性能及酶活性杀死细菌;第7组小鼠伤口在第7天时近乎痊愈,说明该纳米材料在体内同样具有协同效应,具有更强的杀菌性能。
7.2Fe2C@Fe3O4-Ce6异质纳米颗粒的体内荧光成像结果
取10μl Fe2C@Fe3O4-Ce6异质纳米颗粒水溶液滴至被细菌感染的伤口处,用小动物活体成像仪观察伤口处的荧光强度,如图9所示,伤口处呈现明显的荧光,说明纳米材料成功装载了Ce6且所形成的Fe2C@Fe3O4-Ce6异质纳米颗粒在感染部位能够显示荧光,用于指示感染部位,有助于细菌感染的诊断。
7.2 Fe2C@Fe3O4-PEG异质纳米颗粒的毒副作用验证:
每天测量伤口大小时测试小鼠的体重。如图10所示,7组经不同处理方式处理后小鼠体重变化的区别不大。说明这种治疗方法对小鼠的毒副作用不大。
此外,还对7组小鼠经不同处理方式处理7天后,每组各取一只小鼠处死。取心、肝、脾、肺、肾做苏木精-依红(H&E)染色。如图11所示,上述处理方式中这些脏器的染色结果没有明显差异,说明Fe2C@Fe3O4-PEG异质纳米颗粒对这些主要器官的几乎没有副作用。
Claims (7)
1.一种Fe2C@Fe3O4-PEG异质纳米颗粒,其特征在于:将结晶Fe碳化为Fe2C后氧化开孔形成Yolk-Shell结构的Fe2C@Fe3O4异质纳米颗粒,Fe3O4壳布列形状不规则的孔洞,Fe2C@Fe3O4异质纳米颗粒经DIB-PEG-NH2修饰获得,所述Fe2C@Fe3O4-PEG异质纳米颗粒作用条件为808nm近红外光及交变磁场。
2.根据权利要求1所述的Fe2C@Fe3O4-PEG异质纳米颗粒的制备方法,其特征在于:包括如下步骤:
(1)Fe纳米颗粒的合成:
将NH4Br、十八烯(ODE)、油胺(OAm)混合后密封,持续通入Ar/H2,升温后注入Fe(CO)5反应,降温、离心,得Fe纳米粒子,分散于有机溶剂中保存;
(2)Fe2C纳米颗粒的合成:
将十八烯(ODE),油胺(OAm)和(1)中合成的Fe纳米粒子混合后密封,通入Ar/H2、升温,反应完成后降温、离心,将分离出来的Fe2C纳米粒子分散于有机溶剂中保存;
(3)Fe2C@Fe3O4异质纳米颗粒的合成:
将 C3H9NO、十八烯(ODE)、Fe2C纳米粒子混合,通入Ar/H2、升温,反应完成后降温、离心,将分离出来的Fe2C@Fe3O4纳米粒子分散于有机溶剂中保存,
(4)Fe2C@Fe3O4异质纳米颗粒经DIB-PEG-NH2修饰获得。
3.根据权利要求2所述的Fe2C@Fe3O4-PEG异质纳米颗粒的制备方法,其特征在于:将DIB-PEG-NH2溶解,加入含有Fe2C@Fe3O4异质纳米颗粒的氯仿溶液,超声破碎,即得。
4.一种Fe2C@Fe3O4-Ce6异质纳米颗粒,其特征在于:为装载Ce6的权利要求1所述Fe2C@Fe3O4-PEG异质纳米颗粒。
5.根据权利要求4所述的Fe2C@Fe3O4-Ce6异质纳米颗粒的制备方法,其特征在于: 将Fe2C@Fe3O4-PEG、Ce6混合,真空、避光条件下搅拌,即得。
6.根据权利要求1所述的Fe2C@Fe3O4-PEG异质纳米颗粒,其特征在于:具有光热效果、磁热效果、磁光热效果、抗菌效果、类过氧化氢酶活性。
7.根据权利要求4所述的Fe2C@Fe3O4-Ce6异质纳米颗粒,其特征在于:Ce6进入Fe3O4壳的孔洞中,进而能够指示细菌感染部位,作为荧光成像探针。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011184536.5A CN112274639B (zh) | 2020-10-29 | 2020-10-29 | Fe2C@Fe3O4异质纳米颗粒、制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011184536.5A CN112274639B (zh) | 2020-10-29 | 2020-10-29 | Fe2C@Fe3O4异质纳米颗粒、制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112274639A CN112274639A (zh) | 2021-01-29 |
CN112274639B true CN112274639B (zh) | 2023-04-11 |
Family
ID=74352542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011184536.5A Active CN112274639B (zh) | 2020-10-29 | 2020-10-29 | Fe2C@Fe3O4异质纳米颗粒、制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112274639B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114010845A (zh) * | 2021-11-01 | 2022-02-08 | 淮阴工学院 | 一种近红外光响应抗菌涂层及制备方法 |
CN114053473B (zh) * | 2021-11-10 | 2022-10-18 | 昆明理工大学 | 一种四氧化三铁复合纳米酶抗菌剂的制备方法及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107899026A (zh) * | 2017-10-10 | 2018-04-13 | 浙江工业大学 | 一种酸敏感碳化铁纳米材料及其制备方法与应用 |
-
2020
- 2020-10-29 CN CN202011184536.5A patent/CN112274639B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107899026A (zh) * | 2017-10-10 | 2018-04-13 | 浙江工业大学 | 一种酸敏感碳化铁纳米材料及其制备方法与应用 |
Non-Patent Citations (2)
Title |
---|
Multifunctional Magnetic Copper Ferrite Nanoparticles as Fentonlike Reaction and Near-Infrared Photothermal Agents for Synergetic Antibacterial Therapy;Yingnan Liu等;《ACS Applied Materials & Interfaces》;20191231;摘要 * |
Super magnetic Fe3O4-PEG nanoparticles combined with NIR laser and alternating magnetic field as potent anti-cancer agent against human ovarian cancer cells;MajidS.Jabir等;《Materials Research Express》;20191231;Abstract、3.5、Conclusions * |
Also Published As
Publication number | Publication date |
---|---|
CN112274639A (zh) | 2021-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112274639B (zh) | Fe2C@Fe3O4异质纳米颗粒、制备方法及用途 | |
CN110496219B (zh) | 一种新型水铁矿纳米光敏剂的合成方法及其在抗癌抗菌中的应用 | |
CN113234436B (zh) | 一种近红外碳量子点/二氧化硅复合材料及其制备方法和应用 | |
Xin et al. | A robust ROS generation nanoplatform combating periodontitis via sonodynamic/chemodynamic combination therapy | |
WO2022067885A1 (zh) | 掺杂型二氧化钛在制备声敏剂中的应用 | |
Dong et al. | 3D/2D TMSs/TiO2 nanofibers heterojunctions for photodynamic-photothermal and oxidase-like synergistic antibacterial therapy co-driven by VIS and NIR biowindows | |
CN109570488A (zh) | 纳米颗粒及其制备方法和应用、药剂 | |
Li et al. | Sugar-disguised bullets for combating multidrug-resistant bacteria infections based on an oxygen vacancy-engineered glucose-functionalized MoO3-x photo-coordinated bienzyme | |
Geng et al. | Oxygen-carrying biomimetic nanoplatform for sonodynamic killing of bacteria and treatment of infection diseases | |
CN113042076B (zh) | 一种仿过氧化氢酶活性的光催化纳米酶及其制备方法和应用 | |
CN114180621A (zh) | 一种原子分散的钒掺杂二氧化钛及其制备方法和用途 | |
CN110882389B (zh) | 一氧化钛纳米材料及其制备方法和用途 | |
CN117482231A (zh) | 一种应用于肿瘤免疫治疗的多孔铜锰双金属纳米材料及其制备方法 | |
WO2014153774A1 (zh) | 利用自组装的金纳米壳层包覆细菌并借助激光产生光热分解与冷光来杀死与追踪细菌的方法 | |
CN114617964A (zh) | 酶响应性光热纳米材料G@CuS及其制备方法 | |
CN110642865B (zh) | 一种高电荷阳离子卟啉在制备pdt纳米光敏剂中的应用 | |
CN113144175A (zh) | 一种肿瘤微环境响应的co气体治疗剂及其制备方法和应用 | |
Wu et al. | Precise antibacterial therapeutics based on stimuli-responsive nanomaterials | |
CN110240170B (zh) | 一种蛋黄-蛋壳型UCNP@MgSiO3纳米粒子的制备方法 | |
Xu et al. | Precise phase adjustment and antibacterial property of copper sulfide particles in confined mesoporous silica nanoreactor | |
CN114452406B (zh) | 一种抑菌材料及其制备方法和应用 | |
CN116726170A (zh) | 一种复合声敏剂与其细菌靶向的递送系统,及相关制备方法和应用 | |
Liu et al. | An NIR light-driven AgBiS 2@ ZIF-8 hybrid photocatalyst for rapid bacteria-killing | |
CN111214484B (zh) | 一种共轭聚合物和聚集诱导发光小分子共掺的纳米粒子及其制备方法和应用 | |
CN115645599B (zh) | 用于肿瘤切除术后创面修复的热敏凝胶敷料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |